Development and Evaluation of Nasal Formulations of Ketorolac

References

• Aoki, F. Y., and Crawly, J. C. W. 1976. Distribution and removal of human albumin-technetium99m instilled intranasally. Br. J. Clin. Pharmacol. 3:869–878.
   PubMed Web of Science ®Google Scholar
• Berninger, R. W., and Darsh, D. A. 1986. The use of reversed phase cartridges (C18) in processing plasma for analysis of indomethaci n by high performanc e liquid chromatography. J. Clin. Chem. Clin. Biochem. 24:227–232.
   PubMedGoogle Scholar
• Bond, S. W., Hardy, J. G., and Wilson, C. G. 1984. Deposition and clearance of nasal sprays. Proc. 2nd Eur. Congr. Biopharm. Pharmacol. 1:93–98.
   Google Scholar
• Buckley, M. T., and Brogden, N. R. 1990. Ketorolac: a review of its pharma- codynami c and pharmacokineti c properties, and therapeutic potential. Drugs 39(1):86–109.
   Web of Science ®Google Scholar
• Davis, C. P., Torre, R. T., Schafer, C. N., Dave, B., and Bass, B. 1993. Ketorolac as a rapid and effective treatment of migraine headache: evaluation by patients. Ann. Emerg. Med. 11:573–575.
   Web of Science ®Google Scholar
• DeAndrade, R. J., and Maslanka, M. 1994. The use of ketorolac in the manage- ment of postoperative pain. Orthopedics 17:157–166.
   PubMed Web of Science ®Google Scholar
• Dondeti, P., Zia, H., and Needham, T. E. 1995. In vivo evaluation of spray formulations of human insulin for nasal delivery. Int. J. Pharm. 122:91–96.
   Web of Science ®Google Scholar
• El-Hammed, D. M., and Kellaway, W. I. 1997. Preparation and in vitro char- acterization of mucoadhesiv e polymeric microsphere s as intra-nasal delivery systems. Eur. J. Pharm. Bio. 44:53–60.
   Google Scholar
• Gizurason, S. 1990. Animal models for intranasal drug delivery studies. Acta Pharm. Nord. 2(2):106–122.
   Google Scholar
• Gordon, G. S., Moses, A. C., Silver, R. D., Filer, J. S., and Carey, M. D. 1995. Proc. Nat. Acad. Sci. 82:7419–7423.
   Google Scholar
• Gu, L., Chiang, H. S., and Becker, A. 1988. Kinetics and mechanisms of the autoxidation of ketorolac tromethamine in aqueous solution. Int. J. Pharm. 41:95– 104.
   Google Scholar
• Hardy, J. G., Lee, S. W., and Wilson, C. G. 1985. Intranasal drug delivery by spray and drops. J. Pharm. Pharmcol. 37:294–297.
   PubMed Web of Science ®Google Scholar
• Harris, A. S., Svensson, E., Wagner, Z. G., Lethagen, D., and Nilsson, I. M. 1988. Effect of viscosity on the particle size, deposition and clearance of nasal delivery systems containing desmopressin. J. Pharm. Sci. 77:405–408.
   PubMed Web of Science ®Google Scholar
• Harris, S. A., Ohin, M., Svensson, S., Lethagen, D., and Nilsson, I. M. 1989. Effect of viscosity on the pharmacokinetic s and biological response to intranasal desmopressin. J. Pharm. Sci. 78:470–471.
   PubMed Web of Science ®Google Scholar
• Larkin, L. L., and Prescott, J. E. 1992. A randomized double-blind comparative study of the eficacy of ketorolac tromethamine versus meperidine in the treatment of severe migraine. Ann. Emerg. Med. 21(8):919–924.
   PubMed Web of Science ®Google Scholar
• Lee, W. A., Narog, B. A., Patapoff, T. W., and Wang, J. 1991. Intranasal bioavail- ability of insulin powder formulations: effect of permeation enhancer-to- protein ratio. J. Pharm. Sci. 80:725–729.
   PubMed Web of Science ®Google Scholar
• Lin, S. Y., Yu, D. M. S., and Amidon, G. L. 1993. Intranasal gelling delivery systems: a viscoelasticity analysis of nasal residence time. Pharm. Res. 10: S–195.
   Google Scholar
• Marttin, E., Romeijan, G. S., Verhoef, C. J., and Merkus, W. H. M. F. 1997. Nasal absorption of dihydroergotamin e from liquid and powder formulations in rabbit. J. Pharm. Sci. 86:802–807.
   PubMed Web of Science ®Google Scholar
• McMartin, C., Hutchinson, E. F. L., Hyde, R., and Peters, E. G. 1987. Analysis of structural requirements for the absorption of drugs and macromolecules from the nasal cavity. J. Pharm. Sci. 76:535–540.
   PubMed Web of Science ®Google Scholar
• Montgomery, C. D., 1997. Design and analysis of experiments. New York: John Wiley & Sons.
   Google Scholar
• Morimoto, K., Morisaka, K., and Kamada, A. 1985. Enhancemen t of nasal absorption of insulin and calcitonin using polyacrylic acid gel. J. Pharm. Pharmacol. 37:134–136.
   PubMed Web of Science ®Google Scholar
• Morimoto, K., Yamaguchi, H., Iwakura, Y., Morisaka, K., Ohashi, Y., and Nakai, Y. 1991. Effects of viscous hyaluronat e sodium solutions on the nasal absorp- tion of vasopressin and an analogue. Pharm. Res. 8:471–474.
   PubMed Web of Science ®Google Scholar
• Mroszczak, E. J., and Lee, F. W. 1987. Ketorolac tromethamine absorption, distribution, metabolism, excretion, and pharmacokinetic s in animals and hu- mans. Drug Metab. Disp. 15:618–626.
   PubMed Web of Science ®Google Scholar
• Mulvaney, B. D., and Heist, H. E. 1971. Regeneration of rabbit olfactory epithe- lium. Am. J. Anat. 131:241–251.
   PubMedGoogle Scholar
• Nagai, T., Nishimoto, Y., Nambu, N., Suzuki, Y., and Sekine, K. 1984. Powder dosage form of insulin for nasal administration. J. Cont. Release 1:15– 22.
   Google Scholar
• Newman, S. P., Moren, F., and Clarke, S. W. 1987. Deposition pattern from a nasal pump spray. Rhinology 25:77– 82.
   Google Scholar
• Ohwaki, T., Ando, H., Kakimoto, F., Uesugi, K., Watanabe, S., Miyake, Y., and Kayano, M. 1987. Effects of dose, pH, and osmolarity on nasal absorption of secretin in rats. II. Histological aspects of the nasal mucosa in relation to the absorption variation due to the effects of pH and osmolarity. J. Pharm. Sci. 76:695–698.
   PubMed Web of Science ®Google Scholar
• Okuda, M., and Kanda, T. 1973. Scanning electron microscopy of the nasal mucous membrane. Acta Otolaryng. 76:283–294.
   PubMed Web of Science ®Google Scholar
• Pennington, A. K., Ratcliffe, J. H., Wilson, C. G., and Hardy, J. G. 1988. The influence of solution viscosity on nasal spray deposition and clearance. Int. J. Pharm. 43:221– 224.
   Google Scholar
• Peppas, N. A., and Buri, P. A. 1985. Surface interfacial and molecular aspects of polymer bioadhesion on soft tissues. J. Cont. Release 2:257–275.
   Google Scholar
• Quadir, M. 1999. Developmen t of nasal formulations of ketorolac. Ph.D. Dis- sertation, University of Rhode Island, Kingston, RI.
   Google Scholar
• Quadir, M., Needham, T., and Zia, H. (2000). Toxicologica l implication of a newly develope d nasal spray formulation of ketorolac tromethamine. Manuscript under preparation.
   Google Scholar
• Roy, D. S., and Manoukian, E. 1994. Permeability of ketorolac acid and its ester analogs (Prodrug) through human cadaver skin. J. Pharm. Sci. 83:1548–1553.
   PubMed Web of Science ®Google Scholar
• Santus, G., Rivolta, R., and Bottoni, G. 1993. Nasal formulations of ketoro- lac tromethamine, technogica l evaluation—bioavailability and tolerability in rabbits. Farmaco. 48(12):1709–1723.
   PubMedGoogle Scholar
• Yu, D., Sanders, M. L., Davidson, W. R. G., Marvin, J. M., and Ling, T. 1988. Percutaneou s absorption of nicaripine and ketorolac in rhesus monkeys. Pharm. Res. 7:457–462.
   Google Scholar
• Zia, H., Rashed, S., Quadir, M., Needham, E. T., and Squillante, E. 1998. Ketorolac tromethamine and ketoprofen suppositories: release proiles and bioavailability of a cocoa butter base formula in rabbits. Int. J. Pharm. Comp. 2(5):390–393.
   Google Scholar